2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.
Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.
Fuqua says there is a fairly high frequency of this mutation in metastatic breast cancers. These mutations are estrogen independent, meaning that hormones are not needed to activate the receptor. The clinical assumption is that the mutation would confer resistance to an aromatase inhibitor, Fuqua says. However, there is no direct clinical evidence of this because the majority of patients that have been examined have undergone multiple rounds of hormonal therapy.
Related Content: